File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

TitleA controlled trial of interferon with or without prednisone priming for chronic hepatitis B
Authors
Issue Date1992
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro
Citation
Gastroenterology, 1992, v. 102 n. 6, p. 2091-2097 How to Cite?
AbstractIn a randomized, controlled trial of recombinant interferon alfa-2b with or without prednisone priming in Chinese adults with chronic hepatitis B virus infection, stratified randomization for pretreatment serum alanine aminotransferase levels was done. Partial or complete antiviral responses were achieved in 17 (21.5%) of 79 treated patients and 3 (8.3%) of 36 controls (P = 0.14). The response to interferon treatment was significantly better in those who had elevated pretreatment transaminase levels and comparable to that reported in white patients [15 (38.5%) of 39 patients compared with 2 (5%) of 40 who had normal pretreatment transaminase levels (P = 0.0005)]. The spontaneous seroconversion rate was also higher among the controls with elevated transaminase levels [3 (18.8%) of 16 compared with 0 of 20 with normal transaminase levels], but this difference was not statistically significant (P = 0.16). Among the interferon-treated patients, prednisone priming appeared to have a marginal benefit over treatment with interferon alone in patients with elevated transaminase levels (43% vs. 33%), but not in those with normal transaminase levels (0% vs. 9.5%). It was confirmed that Chinese patients with normal transaminase levels respond very poorly to interferon alfa therapy. However, the response was significantly better in patients with elevated transaminase levels.
Persistent Identifierhttp://hdl.handle.net/10722/161934
ISSN
2015 Impact Factor: 18.187
2015 SCImago Journal Rankings: 7.170
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLok, ASFen_US
dc.contributor.authorWu, PCen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorLau, JYNen_US
dc.contributor.authorLeung, EKYen_US
dc.contributor.authorWong, LSKen_US
dc.contributor.authorMa, OCKen_US
dc.contributor.authorLauder, IJen_US
dc.contributor.authorNg, CPLen_US
dc.contributor.authorChung, HTen_US
dc.date.accessioned2012-09-05T05:16:08Z-
dc.date.available2012-09-05T05:16:08Z-
dc.date.issued1992en_US
dc.identifier.citationGastroenterology, 1992, v. 102 n. 6, p. 2091-2097en_US
dc.identifier.issn0016-5085en_US
dc.identifier.urihttp://hdl.handle.net/10722/161934-
dc.description.abstractIn a randomized, controlled trial of recombinant interferon alfa-2b with or without prednisone priming in Chinese adults with chronic hepatitis B virus infection, stratified randomization for pretreatment serum alanine aminotransferase levels was done. Partial or complete antiviral responses were achieved in 17 (21.5%) of 79 treated patients and 3 (8.3%) of 36 controls (P = 0.14). The response to interferon treatment was significantly better in those who had elevated pretreatment transaminase levels and comparable to that reported in white patients [15 (38.5%) of 39 patients compared with 2 (5%) of 40 who had normal pretreatment transaminase levels (P = 0.0005)]. The spontaneous seroconversion rate was also higher among the controls with elevated transaminase levels [3 (18.8%) of 16 compared with 0 of 20 with normal transaminase levels], but this difference was not statistically significant (P = 0.16). Among the interferon-treated patients, prednisone priming appeared to have a marginal benefit over treatment with interferon alone in patients with elevated transaminase levels (43% vs. 33%), but not in those with normal transaminase levels (0% vs. 9.5%). It was confirmed that Chinese patients with normal transaminase levels respond very poorly to interferon alfa therapy. However, the response was significantly better in patients with elevated transaminase levels.en_US
dc.languageengen_US
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastroen_US
dc.relation.ispartofGastroenterologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAlanine Transaminase - Blooden_US
dc.subject.meshChronic Diseaseen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis B - Pathology - Therapyen_US
dc.subject.meshHumansen_US
dc.subject.meshInterferon-Alpha - Adverse Effects - Therapeutic Useen_US
dc.subject.meshLiver - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPrednisone - Therapeutic Useen_US
dc.subject.meshRecombinant Proteinsen_US
dc.titleA controlled trial of interferon with or without prednisone priming for chronic hepatitis Ben_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid1587429-
dc.identifier.scopuseid_2-s2.0-0026602420en_US
dc.identifier.volume102en_US
dc.identifier.issue6en_US
dc.identifier.spage2091en_US
dc.identifier.epage2097en_US
dc.identifier.isiWOS:A1992HW35600035-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLok, ASF=35379868500en_US
dc.identifier.scopusauthoridWu, PC=7403119323en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridLau, JYN=7402446047en_US
dc.identifier.scopusauthoridLeung, EKY=25224640000en_US
dc.identifier.scopusauthoridWong, LSK=7402091922en_US
dc.identifier.scopusauthoridMa, OCK=7004452841en_US
dc.identifier.scopusauthoridLauder, IJ=35564928000en_US
dc.identifier.scopusauthoridNg, CPL=7401705360en_US
dc.identifier.scopusauthoridChung, HT=7404007053en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats